|
1
|
Feng RM, Zong YN, Cao SM and Xu RH: Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 39(22)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 31:3219–3225. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhu XR, Zhu ML, Wang Q, Xue WJ, Wang YW, Wang RF, Chen SY and Zheng LZ: A case report of targeted therapy with apatinib in a patient with advanced gastric cancer and high serum level of alpha-fetoprotein. Medicine (Baltimore). 95(e4610)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bozkaya Y, Demirci NS, Kurtipek A, Erdem GU, Ozdemir NY and Zengin N: Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma. Mol Clin Oncol. 7:267–274. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, Wang J, Xu N, Cheng Y, Bai Y, et al: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): A multicenter, phase II trial. BMC Cancer. 16(68)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Soularue E, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A and André T: for GERCOR. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study. Bull Cancer. 102:324–331. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martinez E, Jorge M, Arrazubi V, Mendez JC, Garcia-Alfonso P, et al: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol. 83:1175–1181. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Takahari D, Chin K, Ishizuka N, Takashima A, Minashi K, Kadowaki S, Nishina T, Nakajima TE, Amagai K, Machida N, et al: Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naive, HER2-positive advanced gastric cancer. Gastric Cancer. 22:1238–1246. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Palle J, Rochand A, Pernot S, Gallois C, Taieb J and Zaanan A: Human Epidermal Growth Factor Receptor 2 (HER2) in advanced gastric cancer: Current knowledge and future perspectives. Drugs. 80:401–415. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kamei S, Kono K, Amemiya H, Takahashi A, Sugai H, Ichihara F, Fujii H and Matsumoto Y: Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein. J Gastroenterol. 38:540–547. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al: The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell. 9:209–223. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pan Z, Lu X, Zhao J, Gao Q and Wang J: VEGF-C is positively associated with lymphangiogenesis and lymphatic metastasis in rectal cancer. Int J Clin Exp Pathol. 11:1777–1783. 2018.PubMed/NCBI
|
|
14
|
Li T, Yu J, Luo X, Ren W, Zhang Y and Cao B: VEGFR-2 as a novel predictor of survival in gastric cancer: A systematic review and meta-analysis. Pathol Res Pract. 214:560–564. 2018.PubMed/NCBI View Article : Google Scholar
|
